Imperative Care Submits IPO Filing Following FDA Approval of Novel Neurovascular Access Catheters for Stroke Treatment

VCBeat (WeChat ID: vcbeat) has learned that on January 24, Imperative Care, a startup specializing in stroke treatment, announced that it had received approval from the U.S. Food and Drug Administration (FDA) to launch its first catheter access products.

Headquartered in California, USA, Imperative Care is dedicated to tackling the challenge of stroke by developing a portfolio of innovative solutions that address the broad and urgent unmet needs in stroke care. The company is committed to transforming stroke treatment through advanced medical technologies, providing healthcare providers with best-in-class devices to elevate the standard of care for stroke patients.

The brain itself is highly complex and features a tortuous vascular architecture, making access to the cerebral vasculature extremely challenging. Imperative Care states that these catheters are designed for interventional therapy in minimally invasive neurovascular procedures for aneurysms, stroke, and other cerebrovascular diseases.

Fred Khosravi, Founder and CEO of Imperative Care, stated in a new press release, “We recognize the significant need and importance of raising the standard of care for stroke patients. Since its inception, Imperative Care has been committed to becoming a comprehensive stroke therapy company, driving innovation across the entire continuum of care. Our therapeutic approach is grounded in a unique clinical perspective, complemented by deep insights into this underserved medical category, with the aim of enabling more patients worldwide to access superior stroke treatment options.”

Imperative Care is the 21st company co-founded by Incept LLC. Incept LLC is a medical technology accelerator and development company that has successfully innovated a variety of medical technologies, treating more than 1 million patients worldwide each year.

“We are now in a brand-new era of stroke treatment. In recent years, more advanced imaging modalities, therapeutic techniques, and high-precision clinical diagnostics have heightened our awareness of the critical importance of timing in intervention, bringing about revolutionary changes in this field. These incremental advances have consistently demonstrated that recanalizing occluded cerebral arteries offers significant advantages in improving patient outcomes, akin to the improved mechanical solutions seen in the treatment of acute myocardial infarction,” emphasized L. Nelson Hopkins, MD, Founder and Chief Scientific Officer of the Jacobs Institute. “Stroke is no longer a sentence of death or disability. With new technologies, more stroke patients will be able to return to normal lives.”

It is understood that Imperative Care’s first product is a neurovascular access catheter, designed to navigate smoothly and steadily into the cerebral vasculature, addressing the challenges of intracranial access. The catheter’s design enables physicians to navigate to the treatment site with greater control and flexibility—critical factors for successful neurovascular procedures—without compromising support or stability. These catheters will be launched in select centers across the United States in the coming months.

“Accessing the brain is an essential first step in any surgical procedure,” said Reade De Leacy, Assistant Professor of Neurosurgery and Radiology and Director of the Mount Sinai Queens Service Line. “Imperative Care’s novel catheter design aims to provide a platform that facilitates physician navigation through complex vasculature. This will help physicians treat patients more rapidly, offering them the best chance for recovery.” It is reported that he performed the first clinical case.

Currently, Imperative Care is developing a suite of technologies designed to help clinicians improve the efficacy and speed of acute stroke treatment, with the goal of achieving better patient outcomes. The company’s near-term pipeline includes an aspiration thrombectomy catheter aimed at facilitating rapid clot removal.